Probiotic Cfu Labeling

A probiotic dietary supplement that carries a CFU (colony-forming unit) claim on its Supplement Facts panel must deliver at least the labelled CFU value through the printed expiration date. Because probiotic strains are living organisms that lose viability over time, the formulation must include sufficient overage at release to compensate for predictable die-off during distribution, storage, and consumer shelf life.

Probiotic viability follows first-order exponential decay (similar to radiopharmaceutical half-life math but at vastly different time-scales):

N(t) = N₀ × e^(−k·t)

• N(t) — viable CFU at time t.
• N₀ — viable CFU at release.
• k — strain- and matrix-specific decay constant (units: 1/month).
• t — time since release.

Probiotic health claims are strain-specific (a benefit observed for L. rhamnosus GG does not transfer to L. rhamnosus GR-1, even though both are the same species). The WHO/FAO 2002 guidelines establish strain-level identification as the regulatory baseline. Typical identity assay hierarchy:

• Genus + species — 16S rRNA sequencing. Standard for component-level identity verification (§111.75(a)(1)(i)).
• Strain — whole-genome sequencing (WGS) + comparison to deposited type strain in ATCC, DSMZ, or BCCM/LMG. Required for premium label claims naming a specific strain (e.g. 'L. rhamnosus GG').
• Phenotypic confirmation — biochemical profile (API 50 CHL), antibiotic-resistance pattern, fermentation profile. Supports but does not replace genetic identification.

Strain names on-label use one of two conventions: ISAPP/WHO-FAO three-part nomenclature (e.g. 'Lactobacillus rhamnosus GG') OR proprietary trade name with the deposited strain name in parentheses (e.g. 'Bifidobacterium lactis HN019 (DR10)'). Brands may not name a strain on-label without traceable identity evidence to the deposited type strain.

Probiotic stability studies adapt ICH Q1A(R2) for supplement use:

• Long-term — labelled storage condition (typically 25°C / 60% RH for shelf-stable, 5°C for refrigerated). 0, 3, 6, 9, 12, 18, 24-month timepoints (and beyond if claiming longer shelf life).
• Accelerated — 40°C / 75% RH for 3–6 months as early shelf-life predictor. Useful for screening formulation variants; NOT a substitute for long-term data for the final label claim.
• Intermediate — 30°C / 65% RH where the labelled condition is 25°C and accelerated shows significant decay.
• In-use — if the consumer is expected to open and re-close (e.g. multi-serving jar), in-use stability after opening (typically 30, 60, 90 days post-open).
• Stress / excursion — short-duration high-temperature (e.g. 50°C for 7 days) to simulate distribution heat excursions; helps justify distribution-condition tolerances.

CFU assay at each timepoint uses USP <2750> plate-count method, typically with selective media per strain (MRS for Lactobacillus, M17 for Streptococcus, MRS-cys for Bifidobacterium). qPCR-based viable-count methods are emerging but USP-validated plate count remains the regulatory standard.

• Label claim at release, not end of shelf life — the most common Warning-Letter pattern. Brand markets '50B CFU' meaning release potency; FDA cites because viable count falls below 50B before expiration.
• Species-only identity — '50B CFU Lactobacillus acidophilus' with no strain identification. FDA considers this insufficient for §111.75 identity unless the formulation is genuinely a mixed-strain feedstock (rare).
• Wrong storage condition — formulation tested at refrigerated (5°C) condition; label says 'store at room temperature'. Stability data does not support the labelled storage.
• Worst-strain ignored — multi-strain blend uses average decay across strains for overage calculation; sensitive strain falls below detectable level long before expiration.
• Moisture intrusion — capsule shell or bottle closure permits moisture in over time; water activity rises above 0.1 threshold; decay accelerates. Often discovered only via in-use stability with simulated consumer-opening behaviour.
• Cross-contamination at release potency assay — competing strains overgrow on non-selective media, inflating apparent count of target strain.
• Dead-cell qPCR over-count — qPCR detects DNA from dead cells as well as live; if assay is reported as viable count without propidium-monoazide treatment, label claim is invalidated.

• Probiotic strain register: per-strain entry with genus + species + strain + deposit reference (ATCC / DSMZ / BCCM), WGS file reference, antibiotic-resistance profile, claimed-benefit clinical references.
• Per-strain decay curve: stability programme outputs first-order decay constant k per strain × matrix × storage condition; stored as a reusable parameter.
• Overage calculator: given label claim, target shelf life, storage condition, and per-strain decay curve, calculates required release CFU per strain. Surfaces the worst-strain-governs warning.
• MMR feasibility check: before MMR approval, V5 confirms calculated release-CFU overage is achievable given strain viability ceiling + capsule/sachet fill volume + matrix water-activity.
• Stability programme tracker: per-product stability schedule with timepoint reminders + CFU assay results + decay-curve update if data deviates from prediction.
• Release potency lock: WO release blocked if release CFU is below the calculated overage-inclusive target for any strain.
• Label-claim audit pack: per-SKU audit pack contains strain identity dossier (WGS + deposit reference), stability data, overage calculation, release-potency lot history — generated as single PDF for FDA inspection / brand audit.
• Recall pre-flight: if a strain's stability programme reveals faster-than-predicted decay, V5 forward-models which lots in market will fall below label claim before expiration and flags for proactive recall vs market action.